Abstract 72P
Background
Ado-trastuzumab emtansine (T-DM1) became the first FDA approved antibody-drug conjugate in breast cancer. This real-world study aimed to evaluate the efficacy and safety of first approved T-DM1 biosimilar (ZRC-3256) in India for HER2-positive breast cancer in routine practice.
Methods
It was a retrospective, single-center, observational study and included patients treated between May 2021 to December 2022. Eligible patients were all female with HER2-positive metastatic breast cancer treated with trastuzumab and taxane prior and at progression treated with standard dose T-DM1 biosimilar. Brain metastasis patients treated with appropriate local therapy were allowed. The primary endpoint includes response rate and progression-free survival (PFS). The secondary endpoints were time to treatment failure (TTF), safety and overall survival (OS). Descriptive statistics were used to recapitulate the patient and other related characteristics. The study was approved by the institute ethics committee.
Results
30 patients treated with T-DM1 biosimilar were included. 5 among them had brain involvement. Median age was 57 years, all had received prior HER2-targeted therapy (100%) and majority of patients (86.67%) were post-menopausal. 83.3% patients received T-DM1 therapy in 2nd line and the complete response rate was 66.63%. Median progression free survival and time to treatment failure were found to be around 13.5 months (95% CI: 13.46 – 17.17) and 13 months (95% CI: 11.47 – 14.53) respectively. Median overall survival data is yet to mature and stand at 24 months (95% CI: 21.03 – 26.97) with limited events. Common adverse events were elevated transaminases, anemia, and thrombocytopenia, with most being manageable and reversible. 10% patients experienced adverse events of Grade 3 or above.
Conclusions
The study findings suggested that T-DM1 is effective in managing HER2-positive metastatic breast cancer and the outcomes with T-DM1 biosimilar usage in the real world are consistent with the published evidence of randomized controlled clinical trials with T-DM1. So, this biosimilar can be a reasonable option in routine clinical practice in India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5P - Clinicopathologic features and genomic profiling of occult breast cancer
Presenter: Liansha Tang
Session: Poster Display
Resources:
Abstract
6P - Tumor cell-released autophagosomes (TRAPs) promote lung metastasis through inducing PD-L1 high expression of pulmonary vascular endothelial cells (PVECs) in breast cancer
Presenter: Xuru Wang
Session: Poster Display
Resources:
Abstract
7P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: Xiaohe Zhou
Session: Poster Display
Resources:
Abstract
9P - Clinicopathological features and prognosis of mucinous breast cancer: A retrospective analysis of 358 patients in Vietnam
Presenter: Hoai Hoang
Session: Poster Display
Resources:
Abstract
10P - Comparison of 28-gene and 70-gene panel in risk-prediction of Chinese women with early-stage HR-positive and HER2-negative breast cancer
Presenter: Lei Lei
Session: Poster Display
Resources:
Abstract
11P - Multimodal analysis of methylation and fragmentomic profiles in plasma cell-free DNA for differentiation of benign and malignant breast tumors
Presenter: Hanh Nguyen
Session: Poster Display
Resources:
Abstract
12P - Plasma cell-free mRNA profiles enable early detection of breast cancer
Presenter: Chi Nguyen
Session: Poster Display
Resources:
Abstract
13P - Relationship of distress and quality of life with gut microbiome composition in newly diagnosed breast cancer patients: A prospective, observational study
Presenter: Chi-Chan Lee
Session: Poster Display
Resources:
Abstract
14P - Classification of molecular subtypes of breast cancer in whole-slide histopathological images using a novel deep learning algorithm
Presenter: Hyung Suk Kim
Session: Poster Display
Resources:
Abstract
15P - The regulation of pregnenolone in breast cancer
Presenter: Hyeon-Gu Kang
Session: Poster Display
Resources:
Abstract